Oculis to Present at the Stifel 2024 Healthcare Conference

Rhea-AI Summary

Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company focused on eye care and sight preservation, has announced its participation in the Stifel 2024 Healthcare Conference. The event will take place on November 18-19, 2024, at the Lotte New York Palace Hotel. Sylvia Cheung, Chief Financial Officer, will participate in a fireside chat on November 18 at 3:35 pm ET. The presentation will be available via live webcast, and the company will conduct one-on-one meetings with investors during the conference. Access to the fireside chat will be provided through Oculis' website under the Investors & Media section.

ZUG, Switzerland, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Oculis’ management will be present at the Stifel 2024 Healthcare Conference being held on November 18-19, 2024 at the Lotte New York Palace Hotel in New York, NY.

Sylvia Cheung, Chief Financial Officer of Oculis, will participate in a fireside chat on November 18, 2024 at 3:35 pm ET. A live webcast of the fireside chat will be available here.

The Company will be available for one-on-one meetings during the conference. Interested investors should contact their Stifel representative to request meetings. A link to access the fireside chat, when available, will be posted to Oculis website on the Events & Presentation page under the Investors & Media section.

About Oculis

Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) purposefully driven to save sight and improve eye care. Oculis’ highly differentiated pipeline comprises multiple innovative product candidates in development. It includes OCS-01, a topical eye drop candidate for diabetic macular edema (DME) and for the treatment of inflammation and pain following cataract surgery; licaminlimab (OCS-02), a topical biologic anti-TNFα eye drop candidate for dry eye disease (DED) and for non-infectious anterior uveitis; and OCS-05, a neuroprotective candidate for acute optic neuritis (AON). Headquartered in Switzerland and with operations in the U.S. and Iceland, Oculis’ goal is to improve the health and quality of life of patients worldwide. The company is led by an experienced management team with a successful track record and is supported by leading international healthcare investors.

For more information, please visit: www.oculis.com.

Oculis Contacts
Ms. Sylvia Cheung, CFO
sylvia.cheung@oculis.com

Investor & Media Relations
LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com
1-212-915-2577

FAQ

When is Oculis (OCS) presenting at the Stifel 2024 Healthcare Conference?

Oculis will present at the Stifel 2024 Healthcare Conference on November 18, 2024, at 3:35 pm ET.

Where can I watch Oculis (OCS) Stifel Conference presentation?

The presentation will be available via live webcast and can be accessed through Oculis' website on the Events & Presentation page under the Investors & Media section.

Who will represent Oculis (OCS) at the Stifel 2024 Healthcare Conference?

Sylvia Cheung, Chief Financial Officer of Oculis, will represent the company in a fireside chat presentation.

How can investors meet with Oculis (OCS) management at the Stifel Conference?

Investors interested in one-on-one meetings should contact their Stifel representative to request meetings during the conference.